Nu-Med Plus Announces Filing of U.S. Provisional Patent Application for Nitric Oxide in Aqueous Solution for Wound Care Treatment
(OTCQB: NUMD), a medical device company which investigates and develops applications and devices for nitric oxide in the medical field, today announced that the Company has filed a U.S. provisional patent application entitled, Kinetically Controlled Method of In Situ Generation of Nitric Oxide in an Aqueous Solution.
- (OTCQB: NUMD), a medical device company which investigates and develops applications and devices for nitric oxide in the medical field, today announced that the Company has filed a U.S. provisional patent application entitled, Kinetically Controlled Method of In Situ Generation of Nitric Oxide in an Aqueous Solution.
- The patent broadly covers the kinetically controlled generation of nitric oxide in an aqueous solution to provide a time dose curve that can be effectively used for treatment of various dermal wounds.
- Jeff Robins, Chief Executive Officer of Nu-Med Plus, stated, This provisional patent application is a major step in the protection of our intellectual property.
- The Utah-based medical device company is currently in the process of filing for FDA approval for their NMP-200 hospital nitric oxide delivery unit.